[1] Lonardo A, Byrne CD, Caldwell SH, et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64: 1388-1389. [2] Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67: 328-357. [3] Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease (NAFLD): a review of epidemiology, risk factors, diagnosis and management. Intern Med J, 2019. [4] 非酒精性脂肪性肝病诊疗指南(2010年修订版).中华肝脏病杂志,2010. [5] Saez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, et al. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. Int J Mol Sci, 2016, 17. [6] Kim D, Touros A, Kim WR. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. Clin Liver Dis, 2018, 22: 133-140. [7] 彭虹,邓蕊,熊晏,等. 实施受控衰减参数在非酒精性脂肪肝诊断中的运用价值. 贵州医药, 2017, 41: 1074-1075. [8] 孙超,范建高. 中外非酒精性脂肪性肝病诊疗指南解读. 中国实用内科杂志, 2019, 39: 235-238. [9] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).临床肝胆病杂志,2018. [10] Xu Y, Ma X, Pan X, et al. Serum adipocyte fatty acid-binding protein levels: An indicator of non-alcoholic fatty liver disease in Chinese individuals. Liver Int, 2019, 39: 568-574. [11] Kim D, Chung GE, Kwak MS, et al. Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol, 2016, 14: 132-138. [12] Du T, Sun X, Yuan G, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism, 2016, 65: 1391-1398. [13] Hossain IA, Rahman SM, Rahman MK, et al. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: Association of GGT and HOMA-IR with NAFLD. Diabetes Metab Syndr, 2016, 10: S25-S29. [14] Kim YC, Cho YK, Lee WY, et al. Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J Nutr Biochem, 2011, 22: 289-292. [15] Kitade H, Chen G, Ni Y, et al. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients, 2017, 9. [16] Hoo RL, Lee IP, Zhou M, et al. Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice. J Hepatol, 2013, 58: 358-364. |